# Ascidian Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ascidian-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.ascidian-tx.com
- Total disclosed funding: $90M
- Latest round: Series A (Nov 8, 2023)
- Investors on record: 1

## About

Based in Boston, US, and founded in 2020, Ascidian Therapeutics, created by ATP, is a biotech company that employs technologies to enable the therapeutic targeting of genes and genes with mutational diversity while preserving native gene expression patterns and levels to provide durability to gene therapy. In November 2023, Ascidian Therapeutics, Inc. raised USD 40 million in series A funding from returning investor Apple Tree Partners. As of October 2022, the firm is being led by Romesh Subramanian as its CEO. 

The firm offers an RNA exon editing platform to create a novel RNA exon editor that offers a single exon editing molecule that can be used to replace several mutant exons via pre-mRNA trans-splicing, without changing DNA or introducing foreign enzymes to help reduce the risks associated with DNA editing and manipulation and has applications in ophthalmology, neurological and neuromuscular disorders, and other rare diseases.

The company intends to use the October 2022 funding to modify the regulations of RNA splicing.

## Funding rounds

- Series A, Nov 8, 2023, $40M — Apple Tree Partners
- Series A, Oct 13, 2022, $50M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A